Within the juvenile idiopathic arthritis subset, “patients had an extremely favorable probability of being neoplasm-free 5 years after initiation of biologics.”
Anti—tumor necrosis factor (anti-TNF) therapy is effective for treating pediatric patients who have rheumatic diseases, but concerns persist about the risk of malignancy associated with these drugs, even though neoplasms are rare in this population. Researchers from The Hospital for Sick Children in Toronto, Ontario, Canada, recently published results of a chart review that assessed pediatric patient data from 357 patients from 1997 to 2013.
These patients, all of whom had rheumatic diseases, were exposed to etanercept, infliximab, adalimumab, golimumab, certolizumab, anakinra, cankinumab, tocilizumab, abatacept, or rituximab, with 21% of the patients having been exposed to more than 1 biologic. The majority of the patients (n = 295) had a diagnosis of juvenile idiopathic arthritis (JIA). The remaining patients had uveitis (n = 23), vasculitis (n = 10), chronic recurrent multifocal osteomyelitis (n = 4), juvenile dermatomyositis (n = 4), systemic lupus erythematosus (n = 4), inflammatory bowel disease-associated arthritis (n = 4), autoinflammatory disease and periodic fever (n = 3), sarcoidosis (n = 3), or another disease (n = 7).
In total, 6 patients were found to have 1 or more neoplasm during or after anti-TNF exposure, resulting in a malignancy rate of 1.68%. The patients who had neoplasms had been exposed to etanercept (n = 1), infliximab (n = 3), or both (n = 2). The median time from anti-TNF initiation to diagnosis with a neoplasm was 5.0 years.
All of these patients had been exposed to methotrexate, and all but 1 received other concomitant medications. It has also been suggested, the authors report, that there may be a background incidence of malignancy in children with inflammatory disease activity, with or without biologic therapy, though studies on this subject have produced conflicting data.
“Most of the neoplasms at our [center] were unusual for the pediatric population,” report the authors. “To the best of our knowledge, this is the first report of benign pilomatricoma and nasopharyngeal carcinoma in a pediatric patient following anti-TNF exposure for rheumatic disease management.”
However, within the JIA subset, “patients had an extremely favorable probability of being neoplasm-free 5 years after initiation of biologics.” Additional long-term studies with larger populations should be completed to identify the types of malignancies that occur in this population, and malignancy screening at each clinical visit is appropriate as part of anti-TNF monitoring of patients receiving biologics.
Reference
Okihiro A, Hasija R, Fung L, et al. Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. Pediatr Rheumatol Online J. 2018;16(1):17. doi: 10.1186/s12969-018-0233-1.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.